Rational treatment of pulmonary infections in patients with cystic fibrosis

Marc Foca, Sujatha Rajan, Lisa Saiman

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


The life expectancy of patients with cystic fibrosis has increased markedly during the past two decades due in large part to improved clinical care, including the use of more effective antimicrobial agents for Pseudomonas. However, the chronic lung disease of CF remains the principal cause of mortality. A growing understanding of the complex interactions between infection and inflammation has led to new approaches for treatment, including chronic use of aerosolized antibiotics, particularly tobramycin, in patients known to be colonized/infected with P. aeruginosa and anti-inflammatory treatments to slow the progression of lung disease.

Original languageEnglish (US)
Pages (from-to)257-263
Number of pages7
JournalCurrent Opinion in Infectious Diseases
Issue number3
StatePublished - 1999
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Rational treatment of pulmonary infections in patients with cystic fibrosis'. Together they form a unique fingerprint.

Cite this